ChemIDplus Advanced United States National Library of Medicine Accessed on 29 Jul 2013 from http://chem.sis.nlm.nih.gov/chemidplus/chemidheavy.jsp. Note: Compound name must be entered under "Substance Identification" and then "Names and Synonyms" selected to view synonyms.
Information on natalizumab (marketed as Tysabri) FDA, 26 Apr 2011 Accessed on 21 Nov 2011 from http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm107198.htm.
Tysabri (natalizumab) Biogen Idec and Elan Pharmaceuticals Accessed on 21 Nov 2011 from http://www.tysabri.com/tysbProject/tysb.portal/_baseurl/threeColLayout/SCSRepository/en_US/tysb/home/index.xml?utm_campaign=Branded&utm_source=google&utm_medium=cpc&utm_content=Tysabri&utm_term=Natalizumab.
New approaches in the management of multiple sclerosis. Barten LJ, Allington DR, Procacci KA, Rivey MP Drug Des Devel Ther. 2010; 4:343-66. Epub 2010 Nov 24. PMID: 21151622. Abstract
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips TJ, Lublin FD, Giovannoni G, Wajgt A, et al. N Engl J Med. 2006 Mar 2; 354(9):899-910. PMID: 16510744. Abstract
Classic Paper Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N Nature. 1992 Mar 5; 356(6364):63-6. PMID: 1538783. Abstract Suggested by Teruna J. SiahaanThis article describes the importance of alpha4-beta1 integrin on leukocyte infiltration through the blood-brain barrier (BBB). This finding was used as the basic principle to develop natalizumab (Tysabri®) for treating MS patients. Natalizumab blocks leukocyte adhesion to vascular endothelium of the BBB and prevents infiltration of leukocytes into the brain.
About Tysabri Biogen Idec and Elan Pharmaceuticals Accessed on 21 Nov 2011 from http://www.tysabri.com/tysbProject/tysb.portal/_baseurl/threeColLayout/SCSRepository/en_US/tysb/home/about-tysabri/index.xml.
An evidence-based review of natalizumab therapy in the management of Crohn's disease. Edula R G, Picco MF Ther Clin Risk Manag. 2009; 5:935-42. Epub 2009 Nov 29. PMID: 20011247. Abstract
Alpha4-integrin antagonism--an effective approach for the treatment of inflammatory diseases? Davenport RJ, Munday JR Drug Discov Today. 2007 Jul; 12(13-14):569-76. Epub 2007 Jun 26. PMID: 17631252. Abstract
Natalizumab in the treatment of rheumatoid arthritis in subjects receiving methotrexate ClinicalTrials.gov, 1 Jun 2009 Accessed on 21 Nov 2011 from http://clinicaltrials.gov/show/NCT00083759.
A controlled trial of natalizumab for relapsing multiple sclerosis. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GPA, Libonati MA, Willmer-Hulme AJ, Dalton CM, Miszkiel KA, O'Connor PW, et al. N Engl J Med. 2003 Jan 2; 348(1):15-23. PMID: 12510038. Abstract
The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Tubridy N, Behan PO, Capildeo R, Chaudhuri A, Forbes R, Hawkins CP, Hughes RA, Palace J, Sharrack B, Swingler R, et al. Neurology. 1999 Aug 11; 53(3):466-72. PMID: 10449105. Abstract
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue E-W, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, et al. N Engl J Med. 2006 Mar 2; 354(9):911-23. PMID: 16510745. Abstract
Tysabri prescribing information Biogen Idec and Elan Pharmaceuticals, Sep 2011 Accessed on 21 Nov 2011 from http://www.tysabri.com/en_US/tysb/site/pdfs/TYSABRI-pi.pdf.
Tysabri Biogen Idec, 2011 Accessed on 21 Nov 2011 from http://www.biogenidec.com/therapies_tysabri.aspx?ID=5589.
A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. Sheremata WA, Vollmer TL, Stone LA, Willmer-Hulme AJ, Koller M Neurology. 1999 Mar 23; 52(5):1072-4. PMID: 10102433. Abstract
Cutting edge: Natalizumab blocks adhesion but not initial contact of human T cells to the blood-brain barrier in vivo in an animal model of multiple sclerosis. Coisne C, Mao W, Engelhardt B J Immunol. 2009 May 15; 182(10):5909-13. PMID: 19414741. Abstract
Treatment with natalizumab in relapsing-remitting multiple sclerosis patients induces changes in inflammatory mechanism. Ramos-Cejudo J, Oreja-Guevara C, Stark Aroeira L, Rodriguez de Antonio L, Chamorro B, Diez-Tejedor E J Clin Immunol. 2011 Aug; 31(4):623-31. Epub 2011 Apr 14. PMID: 21491095. Abstract
Natalizumab treatment reduces endothelial activity in MS patients. Millonig A, Hegen H, Di Pauli F, Ehling R, Gneiss C, Hoelzl M, Künz B, Lutterotti A, Rudzki D, Berger T, et al. J Neuroimmunol. 2010 Oct 8; 227(1-2):190-4. Epub 2010 Aug 23. PMID: 20739072. Abstract
Immune surveillance in multiple sclerosis patients treated with natalizumab. Stüve O, Marra CM, Jerome KR, Cook L, Cravens PD, Cepok S, Frohman EM, Phillips TJ, Arendt G, Hemmer B, et al. Ann Neurol. 2006 May; 59(5):743-7. PMID: 16634029. Abstract
Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Stüve O, Marra CM, Bar-Or A, Niino M, Cravens PD, Cepok S, Frohman EM, Phillips TJ, Arendt G, Jerome KR, et al. Arch Neurol. 2006 Oct; 63(10):1383-7. PMID: 17030653. Abstract
Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS. Rudick RA, Sandrock A Expert Rev Neurother. 2004 Jul; 4(4):571-80. PMID: 15853576. Abstract
Safety and efficacy of natalizumab in children with multiple sclerosis. Ghezzi A, Pozzilli C, Grimaldi LME, Brescia Morra V, Bortolon F, Capra R, Filippi M, Moiola L, Rocca MA, Rottoli M, et al. Neurology. 2010 Sep 7; 75(10):912-7. PMID: 20820002. Abstract
Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis. Rinaldi F, Calabrese M, Seppi D, Puthenparampil M, Perini P, Gallo P Mult Scler. 2012 May 8. PMID: 22570359. Abstract
Editors' Pick Risk of natalizumab-associated progressive multifocal leukoencephalopathy. Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, et al. N Engl J Med. 2012 May 17; 366(20):1870-80. PMID: 22591293. Abstract
Natalizumab-associated reversible encephalopathy syndrome mimicking progressive multifocal leukoencephalopathy. Décard BF, Haghikia A, Tönnes C, Thöne J, Lukas C, Chan A, Gold R Mult Scler. 2012 May 17. PMID: 22596228. Abstract
Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Trampe AK, Hemmelmann C, Stroet A, Haghikia A, Hellwig K, Wiendl H, Goelz S, Ziegler A, Gold R, Chan A Neurology. 2012 May 16. PMID: 22592369. Abstract
Altered microRNA expression in B lymphocytes in multiple sclerosis: Towards a better understanding of treatment effects. Sievers C, Meira M, Hoffmann F, Fontoura P, Kappos L, Lindberg RLP Clin Immunol. 2012 Jul; 144(1):70-9. Epub 2012 May 02. PMID: 22659298. Abstract
Treatments for relapsing-remitting multiple sclerosis: summarising current information by network meta-analysis. Del Santo F, Maratea D, Fadda V, Trippoli S, Messori A Eur J Clin Pharmacol. 2012 Apr; 68(4):441-8. Epub 2011 Nov 05. PMID: 22057838. Abstract
Analysis of T2 intensity by magnetic resonance imaging of deep gray matter nuclei in multiple sclerosis patients: effect of immunomodulatory therapies. Pawate S, Wang L, Song Y, Sriram S J Neuroimaging. 2012 Apr; 22(2):137-44. Epub 2011 Jun 24. PMID: 21707826. Abstract
Peripheral accumulation of newly produced T and B lymphocytes in natalizumab-treated multiple sclerosis patients. Zanotti C, Chiarini M, Serana F, Sottini A, Garrafa E, Torri F, Caimi L, Rasia S, Capra R, Imberti L Clin Immunol. 2012 Jul 21; 145(1):19-26. PMID: 22892399. Abstract
Lipocalin 2 is present in the EAE brain and is modulated by natalizumab. Marques F, Mesquita SD, Sousa JC, Coppola G, Gao F, Geschwind DH, Columba-Cabezas S, Aloisi F, Degn M, Cerqueira JJ, et al. Front Cell Neurosci. 2012; 6:33. Epub 2012 Aug 09. PMID: 22907989. Abstract
Disease-modifying drugs for multiple sclerosis in pregnancy: A systematic review. Lu E, Wang B W, Guimond C, Synnes A, Sadovnick D, Tremlett H Neurology. 2012 Aug 29. PMID: 22933738. Abstract
Natalizumab treatment during pregnancy - effects on the neonatal immune system. Schneider H, Weber CE, Hellwig K, Schroten H, Tenenbaum T Acta Neurol Scand. 2012 Sep 5. PMID: 22950358. Abstract
Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. Vennegoor A, Rispens T, Strijbis E M, Seewann A, Uitdehaag B M, Balk LJ, Barkhof F, Polman CH, Wolbink G, Killestein J Mult Scler. 2012 Sep 19. PMID: 22992450. Abstract
Improved ability to work after one year of natalizumab treatment in multiple sclerosis. Analysis of disease-specific and work-related factors that influence the effect of treatment. Wickström A, Nyström J, Svenningsson A Mult Scler. 2012 Sep 25. PMID: 23012254. Abstract
Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis. Prosperini L, Giannì C, Barletta V, Mancinelli C, Fubelli F, Borriello G, Pozzilli C J Neurol Sci. 2012 Sep 21. PMID: 23006974. Abstract
Editors' Pick Association between Change in Normal Appearing White Matter Metabolites and Intrathecal Inflammation in Natalizumab-Treated Multiple Sclerosis. Mellergård J, Tisell A, Dahlqvist Leinhard O, Blystad I, Landtblom A-M, Blennow K, Olsson B, Dahle C, Ernerudh J, Lundberg P, et al. PLoS One. 2012; 7(9):e44739. Epub 2012 Sep 17. PMID: 23028598. Abstract
Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis. Arnal-Garcia C, García-Montero M R, Málaga I, Millán-Pascual J, Oliva-Nacarino P, Ramió-Torrentà L, Oreja-Guevara C Eur J Paediatr Neurol. 2012 Sep 26. PMID: 23021975. Abstract
Tysabri® (natalizumab) data at ECTRIMS reaffirm positive effects of treatment for people with relapsing forms of MS Biogen Idec, 11 Oct 2012 Accessed on 16 Oct 2012 from http://www.biogenidec.com/PRESS_RELEASE_DETAILS.aspx?ID=5981&ReqId=1744038.
Ongoing clinical trials of TYSABRI Elan Accessed on 16 Oct 2012 from http://www.elan.com/rd/clinical_trials/autoimmune_diseases.asp.
Effects of Tysabri over 12 months on multiple sclerosis (MS) related fatigue in patients with relapsing remitting multiple sclerosis (RRMS) (TYNERGY) ClinicalTrials.gov, 3 Nov 2011 Accessed on 16 Oct 2012 from http://clinicaltrials.gov/ct2/show/NCT00966797.
Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing-remitting multiple sclerosis: a prospective, non-randomized pilot study. Portaccio E, Stromillo M, Goretti B, Hakiki B, Giorgio A, Rossi F, De Leucio A, De Stefano N, Amato MP Eur J Neurol. 2012 Oct 11. PMID: 23057658. Abstract
Natalizumab-induced autoimmune hepatitis in a patient with multiple sclerosis. Martínez-Lapiscina E, Lacruz F, Bolado-Concejo F, Rodríguez-Pérez I, Ayuso T, Garaigorta M, Urman J Mult Scler. 2012 Oct 15. PMID: 23069876. Abstract
Cerebrospinal fluid biomarkers of β-amyloid metabolism in multiple sclerosis. Augutis K, Axelsson M, Portelius E, Brinkmalm G, Andreasson U, Gustavsson MK, Malmeström C, Lycke J, Blennow K, Zetterberg H, et al. Mult Scler. 2012 Oct 15. PMID: 23069872. Abstract
Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy. Harrer A, Tumani H, Niendorf S, Lauda F, Geis C, Weishaupt A, Kleinschnitz C, Rauer S, Kuhle J, Stangel M, et al. Mult Scler. 2012 Oct 23. PMID: 23093485. Abstract
Psoriasis during natalizumab treatment for multiple sclerosis. Millán-Pascual J, Turpín-Fenoll L, Del Saz-Saucedo P, Rueda-Medina I, Navarro-Muñoz S J Neurol. 2012 Oct 25. Epub 2012 Oct 25. PMID: 23096069. Abstract
LETHAL MULTIPLE SCLEROSIS RELAPSE AFTER NATALIZUMAB WITHDRAWAL. Rigau V, Mania A, Béfort P, Carlander B, Jonquet O, Lassmann H, Camu W, Thouvenot E Neurology. 2012 Oct 24. PMID: 23100404. Abstract
Natalizumab treatment of progressive multiple sclerosis (NAPMS) ClinicalTrials.gov, 15 Feb 2012 Accessed on 1 Nov 2012 from http://www.clinicaltrials.gov/ct2/show/NCT01077466.
Analyst insight: ECTRIMS 2012 congress highlights: Promising data offers hope for progressive MS GlobalData, 23 Oct 2012 Accessed on 1 Nov 2012 from http://www.nzdoctor.co.nz/un-doctored/2012/october-2012/23/analyst-insight-ectrims-2012-congress-highlights-promising-data-offers-hope-for-progressive-ms.aspx.
Changes in JC Virus-Specific T Cell Responses during Natalizumab Treatment and in Natalizumab-Associated Progressive Multifocal Leukoencephalopathy. Perkins MR, Ryschkewitsch C, Liebner JC, Monaco M CG, Himelfarb D, Ireland S, Roque A, Edward HL, Jensen PN, Remington G, et al. PLoS Pathog. 2012 Nov; 8(11):e1003014. Epub 2012 Nov 08. PMID: 23144619. Abstract
Editors' Pick Effect of Natalizumab on Circulating CD4(+) T-Cells in Multiple Sclerosis. Börnsen L, Romme Christensen J, Ratzer R, Oturai A B, Sørensen P S, Søndergaard H B, Sellebjerg F PLoS One. 2012; 7(11):e47578. Epub 2012 Nov 30. PMID: 23226199. Abstract
A case of natalizumab-associated progressive multifocal leukoencephalopathy with repeated negative CSF JC virus testing. Mazda ME, Brosch JR, Wiens AL, Bonnin J, Kamer AP, Mattson DH, Snook RJ Int J Neurosci. 2012 Dec 20. PMID: 23252596. Abstract
Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal study. Stephenson JJ, Kern DM, Agarwal SS, Zeidman R, Rajagopalan K, Kamat SA, Foley J Health Qual Life Outcomes. 2012 Dec 27; 10(1):155. Epub 2012 Dec 27. PMID: 23270428. Abstract
Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis. Benkert TF, Dietz L, Hartmann EM, Leich E, Rosenwald A, Serfling E, Buttmann M, Berberich-Siebelt F PLoS One. 2012; 7(12):e52208. Epub 2012 Dec 20. PMID: 23284936. Abstract
Editors' Pick Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Yousry TA, Pelletier D, Cadavid D, Gass A, Richert ND, Radue E-W, Filippi M Ann Neurol. 2012 Nov; 72(5):779-87. Epub 1969 Dec 31. PMID: 23280794. Abstract
Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis. Cadavid D, Jurgensen S, Lee S PLoS One. 2013; 8(1):e53297. Epub 2013 Jan 04. PMID: 23308186. Abstract
Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis. Phillips TJ, Giovannoni G, Lublin FD, O'Connor PW, Polman CH, Willoughby E, Aschenbach W, Pace A, Hyde R, Munschauer FE Mult Scler. 2011 Aug; 17(8):970-9. Epub 2011 Mar 18. PMID: 21421809. Abstract
Clinical effects of natalizumab on multiple sclerosis appear early in treatment course. Kappos L, O'Connor PW, Polman CH, Vermersch P, Wiendl H, Pace A, Zhang A, Hotermans C J Neurol. 2013 Jan 5. Epub 2013 Jan 05. PMID: 23292204. Abstract
Presumptive Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis after Natalizumab Therapy. Eisele P, Szabo K, Hornberger E, Griebe M, Hennerici MG, Kieseier BC, Gass A J Neuroimaging. 2013 Jan 16. PMID: 23323645. Abstract
Immune cells after prolonged Natalizumab therapy: implications for effectiveness and safety. Marousi S, Karkanis I, Kalamatas T, Travasarou M, Paterakis G, Karageorgiou CE Acta Neurol Scand. 2013 Jan 11. PMID: 23311457. Abstract
Biogen Idec and Elan submit applications for first-line use of Tysabri in anti-JCV antibody negative patients with MS Biogen Idec, 16 Jan 2013 Accessed on 21 Jan 2013 from http://www.biogenidec.com/PRESS_RELEASE_DETAILS.aspx?ID=5981&ReqId=1774946.
Switching from natalizumab to fingolimod: an observational study. Sempere AP, Martín-Medina P, Berenguer-Ruiz L, Pérez-Carmona N, Sanchez-Perez R, Polache-Vengud J, Feliu-Rey E Acta Neurol Scand. 2013 Jan 22. PMID: 23336398. Abstract
Effects of natalizumab treatment on the CSF proteome of multiple sclerosis patients. Stoop MP, Singh V, Stingl C, Martin R, Khademi M, Olsson T, Hintzen R, Luider TM J Proteome Res. 2013 Jan 22. PMID: 23339689. Abstract
Biogen Idec to acquire full rights and control of Tysabri from Elan for upfront cash and contingent payments Biogen Idec, 6 Feb 2013 Accessed on 11 Feb 2013 from http://www.biogenidec.com/PRESS_RELEASE_DETAILS.aspx?ID=5981&ReqId=1781970.
Fatal Neuroinflammation in a Case of Multiple Sclerosis with Anti-Natalizumab Antibodies. Svenningsson A, Dring AM, Fogdell-Hahn A, Jones I, Engdahl E, Lundkvist M, Brännström T, Gilthorpe JD Neurology. 2013 Feb 6. PMID: 23390173. Abstract
Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases. Ghezzi A, Pozzilli C, Grimaldi LME, Moiola L, Brescia-Morra V, Lugaresi A, Lus G, Rinaldi F, Rocca MA, Trojano M, et al. Mult Scler. 2013 Feb 11. PMID: 23401129. Abstract
Elan provides update post restructuring announcement of Tysabri collaboration Elan Corporation, 22 Feb 2013 Accessed on 27 Feb 2013 from http://newsroom.elan.com/phoenix.zhtml?c=88326&p=irol-newsArticle&ID=1787913.
Natalizumab Therapy for Highly Active Pediatric Multiple Sclerosis. Kornek B, Aboul-Enein F, Rostasy K, Milos R-I, Steiner I, Penzien J, Hellwig K, Pitarokoili K, Van's Gravesande K S, Karenfort M, et al. JAMA Neurol. 2013 Feb 18:1-7. PMID: 23420110. Abstract
Tysabri may be option for kids with MS Gever J, MedPage Today, 19 Feb 2013 Accessed on 27 Feb 2013 from http://www.medpagetoday.com/clinical-context/MultipleSclerosis/37436.
Presymptomatic diagnosis with MRI and adequate treatment ameliorate the outcome after natalizumab-associated progressive multifocal leukoencephalopathy. Lindå H, von Heijne A Front Neurol. 2013; 4:11. Epub 2013 Feb 18. PMID: 23423248. Abstract
Report of Three Cases of Herpes Zoster During Treatment with Natalizumab. Fragoso Y D, Brooks J B B, Gomes S, de Oliveira F T M, da Gama P D CNS Neurosci Ther. 2013 Feb 18. PMID: 23419219. Abstract
Early detection of MS treatment complication may improve survival Market Watch, The Wall Street Journal, 10 Mar 2013 Accessed on 13 Mar 2013 from http://www.marketwatch.com/story/early-detection-of-ms-treatment-complication-may-improve-survival-2013-03-10.
Changes to anti-JCV antibody levels in a Swedish national MS cohort. Warnke C, Ramanujam R, Plavina T, Bergström T, Goelz S, Subramanyam M, Kockum I, Rahbar A, Kieseier BC, Holmén C, et al. J Neurol Neurosurg Psychiatry. 2013 Mar 5. PMID: 23463870. Abstract
Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. Olsson T, Achiron A, Alfredsson L, Berger T, Brassat D, Chan A, Comi G, Eraksoy M, Hegen H, Hillert J, et al. Mult Scler. 2013 Mar 4. PMID: 23459571. Abstract
Editors' Pick Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients. Selter RC, Biberacher V, Grummel V, Buck D, Eienbröker C, Oertel WH, Berthele A, Tackenberg B, Hemmer B Mult Scler. 2013 Feb 25. Epub 1969 Dec 31. PMID: 23439578. Abstract
Clinical predictors of an optimal response to natalizumab in multiple sclerosis. Sargento-Freitas J, Batista S, Macario C, Matias F, Sousa L J Clin Neurosci. 2013 Feb 25. PMID: 23485407. Abstract
The role of natural killer cells in multiple sclerosis and their therapeutic implications. Chanvillard C, Jacolik RF, Infante-Duarte C, Nayak RC Front Immunol. 2013; 4:63. Epub 2013 Mar 13. PMID: 23493880. Abstract
New Tysabri data reaffirm substantial efficacy in treatment of people with MS and demonstrate stability of anti-JCV antibody status Biogen Idec, 18 Mar 2013 Accessed on 21 Mar 2013 from http://www.biogenidec.com/PRESS_RELEASE_DETAILS.aspx?ID=5981&ReqId=1797077.
Immunological Hallmarks of JC Virus Replication in Multiple Sclerosis Patients on Long-Term Natalizumab. Hendel-Chavez H, de Goër de Herve M-G, Giannesini C, Mazet A-A, Papeix C, Louapre C, Chardain A, Boutarfa N, Théaudin M, Adams D, et al. J Virol. 2013 Mar 20. PMID: 23514886. Abstract
Editors' Pick The Australian Multiple Sclerosis (MS) Immunotherapy Study: A Prospective, Multicentre Study of Drug Utilisation Using the MSBase Platform. Jokubaitis VG, Spelman T, Lechner-Scott J, Barnett M, Shaw C, Vucic S, Liew D, Butzkueven H, Slee M, Slee M PLoS One. 2013; 8(3):e59694. Epub 2013 Mar 19. PMID: 23527252. Abstract
Low body weight linked to PML risk with natalizumab in MS Medscape Today, 3 Apr 2013 Accessed on 8 Apr 2013 from http://www.medscape.com/viewarticle/781879.
Biogen Idec completes purchase of full rights and control of Tysabri® Biogen Idec, 2 Apr 2013 Accessed on 8 Apr 2013 from http://www.biogenidec.com/PRESS_RELEASE_DETAILS.aspx?ID=5981&ReqId=1802638.
Natalizumab Treatment Reduces Fatigue in Multiple Sclerosis. Results from the TYNERGY Trial; A Study in the Real Life Setting. Svenningsson A, Falk E, Celius EG, Fuchs S, Schreiber K, Berkö S, Sun J, Penner I-K, Penner I-K PLoS One. 2013; 8(3):e58643. Epub 2013 Mar 21. PMID: 23555589. Abstract
Varicella-zoster virus acute myelitis in a patient with MS treated with natalizumab. Yeung J, Cauquil C, Saliou G, Nasser G, Rostomashvili S, Adams D, Théaudin M Neurology. 2013 Apr 24. PMID: 23616161. Abstract
TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab. Oreja-Guevara C, Ramos-Cejudo J, Stark Aroeira L, Chamorro B, Diez-Tejedor E BMC Neurol. 2012; 12:95. Epub 2012 Sep 18. PMID: 22989378. Abstract
The chemokine receptor CCR5 Δ32 allele in natalizumab-treated multiple sclerosis. Møller M, Søndergaard HB, Koch-Henriksen N, Sorensen PS, Sellebjerg F, Oturai AB Acta Neurol Scand. 2013 May 14. PMID: 23668375. Abstract
Tysabri screening test may be unreliable Gever J, Medpage Today, 5 Jun 2013 Accessed on 7 Jun 2013 from http://www.medpagetoday.com/Neurology/MultipleSclerosis/39649.
JC viremia in natalizumab-treated patients with multiple sclerosis. Major EO, Frohman E, Douek D N Engl J Med. 2013 Jun 6; 368(23):2240-1. PMID: 23738566. Abstract
Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Filippini G, Giovane C D, Vacchi L, D'Amico R, Di Pietrantonj C, Beecher D, Salanti G Cochrane Database Syst Rev. 2013 Jun 6; 6:CD008933. PMID: 23744561. Abstract
Central Nervous System Herpes Simplex and Varicella-Zoster Virus Infections in Natalizumab-Treated Patients. Fine AJ, Sorbello A, Kortepeter C, Scarazzini L Clin Infect Dis. 2013 May 31. PMID: 23728144. Abstract
Comparative effectiveness of early Natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis. Campbell JD, McQueen BR, Miravalle A, Corboy JR, Ackermann RT, Vollmer TL, Nair K Am J Manag Care. 2013; 19(4):278-85. PMID: 23725360. Abstract
Early development of anti-natalizumab antibodies in MS patients. Oliver-Martos B, Orpez-Zafra T, Urbaneja P, Maldonado-Sanchez R, Leyva L, Fernández O J Neurol. 2013 Jun 14. Epub 2013 Jun 14. PMID: 23765090. Abstract
Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis. Kuhle J, Malmeström C, Axelsson M, Plattner K, Yaldizli O, Derfuss T, Giovannoni G, Kappos L, Lycke J Acta Neurol Scand. 2013 Jun 13. PMID: 23763388. Abstract
Recurrent disease-activity rebound in a patient with multiple sclerosis after natalizumab discontinuations for pregnancy planning. Martinelli V, Colombo B, Dalla Costa G, Dalla Libera D, Moiola L, Falini A, Comi G, Filippi M Mult Scler. 2013 Jun 17. PMID: 23773984. Abstract
JCV test stratifies PML risk in antibody-positive MS Keller DM, Medscape Today, 14 Jun 2013 Accessed on 24 Jun 2013 from http://www.medscape.com/viewarticle/806294.
Immune reconstitution inflammatory syndrome in a patient treated with natalizumab presenting progressive multifocal leukoencephalopathy. Métivier D, Arnaud F-X, Dutasta F, Nguema B, Teriitehau C, Berets O, Baccialone J, Potet J Diagn Interv Imaging. 2013 Jan; 94(1):101-3. Epub 2012 Dec 08. PMID: 23228283. Abstract
Acquired perforating dermatosis associated with natalizumab. Piqué-Duran E, Eguía P, García-Vázquez O J Am Acad Dermatol. 2013 Jun; 68(6):e185-7. PMID: 23680214. Abstract
Natalizumab inhibits the expression of human endogenous retroviruses of the W family in multiple sclerosis patients: a longitudinal cohort study. Arru G, Leoni S, Pugliatti M, Mei A, Serra C, Delogu L G, Manetti R, Dolei A, Sotgiu S, Mameli G Mult Scler. 2013 Jul 22. PMID: 23877972. Abstract
JCV granule cell neuronopathy and GCN-IRIS under natalizumab treatment. Schippling S, Kempf C, Büchele F, Jelcic I, Bozinov O, Bont A, Linnebank M, Sospedra M, Weller M, Budka H, et al. Ann Neurol. 2013 Jul 19. PMID: 23868420. Abstract
Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial. Gobbi C, Meier DS, Cotton F, Sintzel M, Leppert D, Guttmann CRG, Zecca C BMC Neurol. 2013; 13:101. Epub 2013 Aug 02. PMID: 23915113. Abstract
A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort. Outteryck O, Ongagna JC, Brochet B, Rumbach L, Lebrun-Frenay C, Debouverie M, Zéphir H, Ouallet JC, Berger E, Cohen M, et al. Eur J Neurol. 2013 Jun 12. PMID: 23895407. Abstract
Neuroborreliosis during natalizumab treatment in multiple sclerosis. Thomas K, Schultheiss T, Ziemssen T Neurology. 2013 Jul 26. PMID: 23892705. Abstract
L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Schwab N, Schneider-Hohendorf T, Posevitz V, Breuer J, Göbel K, Windhagen S, Brochet B, Vermersch P, Lebrun-Frenay C, Posevitz-Fejfár A, et al. Neurology. 2013 Sep 3; 81(10):865-71. Epub 2013 Aug 07. PMID: 23925765. Abstract
Risk factors for rare diseases can be risky to define: PML and natalizumab. Major EO, Douek DC Neurology. 2013 Aug 7. PMID: 23925759. Abstract
Editors' Pick A network meta-analysis of randomized controlled trials for comparing the effectiveness and safety profile of treatments with marketing authorization for relapsing multiple sclerosis. Hadjigeorgiou GM, Doxani C, Miligkos M, Ziakas P, Bakalos G, Papadimitriou D, Mprotsis T, Grigoriadis N, Zintzaras E J Clin Pharm Ther. 2013 Aug 20. PMID: 23957759. Abstract
Asymptomatic lung disease caused by Mycobacterium kansasii as an opportunistic infection in a patient treated with natalizumab for relapsing-remitting multiple sclerosis. Hradilek P, Zeman D, Tudik I, Zapletalova O, Ulmann V Mult Scler. 2013 Aug 19. PMID: 23959714. Abstract
Effect of natalizumab on oxidative damage biomarkers in relapsing-remitting multiple sclerosis. Tasset I, Bahamonde C, Agüera E, Conde C, Cruz AH, Pérez-Herrera A, Gascón F, Giraldo AI, Ruiz MC, Lillo R, et al. Pharmacol Rep. 2013; 65(3):634-1. PMID: 23950585. Abstract
Epithelial v-like antigen mediates efficacy of anti-alpha4 integrin treatment in a mouse model of multiple sclerosis. Wright E, Rahgozar K, Hallworth N, Lanker S, Carrithers MD PLoS One. 2013; 8(8):e70954. Epub 2013 Aug 08. PMID: 23951051. Abstract
Post-natalizumab clinical and radiological findings in a cohort of multiple sclerosis patients: 12-month follow-up. Melis M, Cocco E, Frau J, Lorefice L, Fenu G, Coghe G, Mura M, Marrosu M G Neurol Sci. 2013 Aug 30. Epub 2013 Aug 30. PMID: 23990111. Abstract
Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development. Kivisäkk P, Healy BC, Francois K, Gandhi R, Gholipour T, Egorova S, Sevdalinova V, Quintana F, Chitnis T, Weiner HL, et al. Mult Scler. 2013 Sep 4. PMID: 24005026. Abstract
The improvement of cognitive functions is associated with a decrease of plasma Osteopontin levels in Natalizumab treated relapsing multiple sclerosis. Iaffaldano P, Ruggieri M, Viterbo R G, Mastrapasqua M, Trojano M Brain Behav Immun. 2013 Aug 30. PMID: 23994630. Abstract
JC-virus seroconversion in multiple sclerosis patients receiving natalizumab. Outteryck O, Zéphir H, Salleron J, Ongagna J-C, Etxeberria A, Collongues N, Lacour A, Fleury M-C, Blanc F, Giroux M, et al. Mult Scler. 2013 Sep 26. PMID: 24072722. Abstract
Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal? Wipfler P, Harrer A, Pilz G, Oppermann K, Afazel S, Haschke-Becher E, Sellner J, Trinka E, Kraus J Acta Neurol Scand. 2013 Aug 30. PMID: 24032536. Abstract
Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis. Warnke C, Mausberg AK, Stettner M, Dehmel T, Nekrich L, Meyer Zu Horste G, Hartung H-P, Fogdell-Hahn A, Adams O, Kieseier BC Neurology. 2013 Sep 18. PMID: 24049136. Abstract
A bird's-eye view of T cells during natalizumab therapy. Hohlfeld R, Stüve O Neurology. 2013 Sep 18. PMID: 24049137. Abstract
How Natalizumab Binds and Antagonizes α4 Integrins. Yu Y, Schürpf T, Springer TA J Biol Chem. 2013 Sep 18. PMID: 24047894. Abstract
New TYSABRI® data show earlier treatment and longer-term use result in significant reductions in MS disease activity Biogen Idec, 3 Oct 2013 Accessed on 4 Oct 2013 from http://www.biogenidec.com/press_release_details.aspx?ID=5981&ReqId=1861119.
Shorter washout reduces MS relapse switching off natalizumab Hughes S, Medscape, 7 Oct 2013 Accessed on 10 Oct 2013 from http://www.medscape.com/viewarticle/812174.
IgM antibody identifies good candidates for natalizumab Hughes S, Medscape, 8 Oct 2013 Accessed on 10 Oct 2013 from http://www.medscape.com/viewarticle/812244.
Does jcv antibody positivity encourage cessation of natalizumab therapy in multiple sclerosis? Lonergan R, Kinsella K, Kelly S, Duggan M, Scott J, O'Rourke K, Lynch T, Hutchinson M, Tubridy N, McGuigan C J Neurol Neurosurg Psychiatry. 2013 Nov; 84(11):e2. PMID: 24108958. Abstract
Immunological and clinical consequences of splenectomy in a multiple sclerosis patient treated with natalizumab. Lee D-H, Waschbisch A, Lämmer AB, Doerfler A, Schwab S, Linker RA J Neuroinflammation. 2013 Oct 9; 10(1):123. Epub 2013 Oct 09. PMID: 24107235. Abstract
Efficacy and safety of natalizumab treatment for relapsing-remitting multiple sclerosis: interim results of the tysabri(r) observational programme in the uk. Hanna J, Rosen J P, Smethurst C J Neurol Neurosurg Psychiatry. 2013 Nov; 84(11):e2. PMID: 24108955. Abstract
Natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis: a postmortem study. Wüthrich C, Popescu B GF, Gheuens S, Marvi M, Ziman R, Denq S P, Tham M, Norton E, Parisi JE, Dang X, et al. J Neuropathol Exp Neurol. 2013 Nov; 72(11):1043-51. PMID: 24128680. Abstract
Brainstem PML lesion mimicking MS plaque in a natalizumab-treated MS patient. Tortorella C, Direnzo V, D'Onghia M, Trojano M Neurology. 2013 Oct 15; 81(16):1470-1. PMID: 24127190. Abstract
Disease Modifying Therapies Modulate Cardiovascular Risk Factors in Multiple Sclerosis Patients. Sternberg Z, Leung C, Sternberg D, Yu J, Hojnacki D Cardiovasc Ther. 2013 Oct 1. PMID: 24119301. Abstract
Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States. Bonafede MM, Johnson BH, Wenten M, Watson C Clin Ther. 2013 Oct; 35(10):1501-12. PMID: 24139422. Abstract
Antibody index test may aid PML diagnosis on natalizumab Hughes S, Medscape, 30 Oct 2013 Accessed on 5 Nov 2013 from http://www.medscape.com/viewarticle/813469.
Editors' Pick Efficacy and safety of BG-12 (dimethyl fumarate) and other disease modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison. Hutchinson M, Fox RJ, Havrdova E, Kurukulasuriya NC, Sarda SP, Agarwal S, Siddiqui M K, Taneja A, Deniz B Curr Med Res Opin. 2013 Nov 7. Epub 1969 Dec 31. PMID: 24195574. Abstract
Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy. Carruthers RL, Chitnis T, Healy BC Mult Scler. 2013 Nov 4. PMID: 24189572. Abstract
Progressive multifocal leukoencephalopathy after natalizumab discontinuation. Fine AJ, Sorbello A, Kortepeter C, Scarazzini L Ann Neurol. 2013 Nov 16. PMID: 24242357. Abstract
A benefit-risk analysis of natalizumab in the treatment of patients with multiple sclerosis when considering the risk of progressive multifocal leukoencephalopathy. Walker A, Watson C, Alexopoulos ST, Deniz B, Arnold R, Bates D Curr Med Res Opin. 2013 Dec 5. PMID: 24289170. Abstract
Increased B cell and cytotoxic NK cell proportions and increased T cell responsiveness in blood of natalizumab-treated multiple sclerosis patients. Mellergård J, Edström M, Jenmalm MC, Dahle C, Vrethem M, Ernerudh J PLoS One. 2013; 8(12):e81685. Epub 2013 Dec 02. PMID: 24312575. Abstract
Smokers run increased risk of developing anti-natalizumab antibodies. Hedström A, Alfredsson L, Lundkvist Ryner M, Fogdell-Hahn A, Hillert J, Olsson T Mult Scler. 2013 Dec 5. PMID: 24311118. Abstract
A possible case of natalizumab-dependent suicide attempt: A brief review about drugs and suicide. Mumoli L, Ciriaco M, Gambardella A, Bombardiere G N, Valentino P, Palleria C, Labate A, Russo E J Pharmacol Pharmacother. 2013 Dec; 4(Suppl 1):S90-3. PMID: 24347991. Abstract
Health care-resource utilization before and after natalizumab initiation in multiple sclerosis patients in the US. Bonafede MM, Johnson BH, Watson C Clinicoecon Outcomes Res. 2013; 6:11-20. Epub 2013 Dec 19. PMID: 24379685. Abstract
Reduced sick leave in multiple sclerosis after one year of natalizumab treatment. A prospective ad hoc analysis of the TYNERGY trial. Wickström A, Dahle C, Vrethem M, Svenningsson A Mult Scler. 2013 Dec 30. PMID: 24378984. Abstract
Eosinophilic Fasciitis Occurring under Treatment with Natalizumab for Multiple Sclerosis. Bujold J, Boivin C, Amin M, Bouchard J-P, Soucy J J Cutan Med Surg. 2014; 18:69-71. PMID: 24377479. Abstract
Central nervous system lymphoma associated with natalizumab. Na A, Hall N, Kavar B, King J J Clin Neurosci. 2013 Nov 9. PMID: 24373819. Abstract
JCV-negative natalizumab-associated progressive multifocal leukoencephalopathy: a clinico-radiological diagnosis. Travasarou M, Marousi S, Papageorgiou E, Karageorgiou CE Clin Neurol Neurosurg. 2013 Jun; 115(6):827-9. Epub 2012 Aug 21. PMID: 22920632. Abstract
Long term follow up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab. Koudriavtseva T, Sbardella E, Trento E, Bordignon V, D'Agosto G, Cordiali-Fei P Clin Exp Immunol. 2014 Jan 6. PMID: 24387139. Abstract
Low vitamin D level is associated with higher relapse rate in natalizumab treated MS patients. Scott TF, Hackett CT, Dworek DC, Schramke CJ J Neurol Sci. 2013 Jul 15; 330(1-2):27-31. Epub 2013 Apr 18. PMID: 23602794. Abstract
Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study. Olberg HK, Cox RJ, Nostbakken JK, Aarseth JH, Vedeler CA, Myhr K-M Mult Scler. 2014 Jan 16. PMID: 24436455. Abstract 1 member recommends
Changes in Fatigue and Cognition in Patients with Relapsing Forms of Multiple Sclerosis Treated with Natalizumab: The ENER-G Study. Wilken J, Kane RL, Sullivan CL, Gudesblatt M, Lucas S, Fallis R, You X, Foulds P Int J MS Care. 2013 Fall; 15(3):120-8. PMID: 24453774. Abstract
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis (ASCEND in SPMS) ClinicalTrials.gov, 12 Sep 2013 Accessed on 6 Feb 2014 from http://clinicaltrials.gov/show/NCT01416181.
Varicella zoster-associated retinal and central nervous system vasculitis in a patient with multiple sclerosis treated with natalizumab. Kobeleva X, Wegner F, Brunotte I, Dadak M, Dengler R, Stangel M J Neuroinflammation. 2014; 11(1):19. Epub 2014 Jan 30. PMID: 24479415. Abstract
Integrin/Chemokine Receptor Interactions in the Pathogenesis of Experimental Autoimmune Encephalomyelitis. Banisadr G, Schwartz SR, Podojil JR, Piccinini LA, Lanker S, Miller SD, Miller RJ J Neuroimmune Pharmacol. 2014 Jan 30. Epub 2014 Jan 30. PMID: 24477403. Abstract
Dual-Task Assessment in Natalizumab-Treated Multiple Sclerosis Patients. Allali G, Laidet M, Assal F, Chofflon M, Armand S, Lalive PH Eur Neurol. 2014 Feb 1; 71(5-6):149-153. Epub 2014 Feb 01. PMID: 24503719. Abstract
The anti-VLA-4 antibody natalizumab induces erythroblastaemia in the majority of the treated patients with multiple sclerosis. Robier C, Amouzadeh-Ghadikolai O, Bregant C, Diez J, Melinz K, Neubauer M, Quasthoff S Mult Scler. 2014 Feb 3. PMID: 24493472. Abstract
Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis. Amor S, van der Star BJ, Bosca I, Raffel J, Gnanapavan S, Watchorn J, Kuhle J, Giovannoni G, Baker D, Malaspina A, et al. Mult Scler. 2014 Feb 10. PMID: 24515731. Abstract
Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. Butzkueven H, Kappos L, Pellegrini F, Trojano M, Wiendl H, Patel RN, Zhang A, Hotermans C, Belachew S, on behalf of the TYSABRI Observational Program(TOP) Investigators J Neurol Neurosurg Psychiatry. 2014 Feb 14. PMID: 24532785. Abstract
Normal outcome of pregnancy with ongoing treatment with natalizumab. Fagius J, Burman J Acta Neurol Scand. 2014 Feb 15. PMID: 24527849. Abstract
Treatment satisfaction, adherence and behavioral assessment in patients de - escalating from natalizumab to interferon beta. Zecca C, Riccitelli GC, Calabrese P, Pravatà E, Candrian U, Guttmann CRG, Gobbi C BMC Neurol. 2014; 14(1):38. Epub 2014 Feb 28. PMID: 24576156. Abstract
Editors' Pick Switching From Natalizumab to Fingolimod in Multiple Sclerosis: A French Prospective Study. Cohen M, Maillart E, Tourbah A, De Sèze J, Vukusic S, Brassat D, Anne O, Wiertlewski S, Camu W, Courtois S, et al. JAMA Neurol. 2014 Feb 24. Epub 1969 Dec 31. PMID: 24566807. Abstract
MiR-126: a novel route for natalizumab action? Meira M, Sievers C, Hoffmann F, Derfuss T, Kuhle J, Kappos L, Lindberg RLP Mult Scler. 2014 Mar 5. PMID: 24598267. Abstract
First-line natalizumab in multiple sclerosis: rationale, patient selection, benefits and risks. Nicholas J A, Racke M K, Imitola J, Boster A L Ther Adv Chronic Dis. 2014 Mar; 5(2):62-68. PMID: 24587891. Abstract
Elevated melatonin levels in natalizumab-treated female patients with relapsing-remitting multiple sclerosis: Relationship to oxidative stress. Bahamonde C, Conde C, Agüera E, Lillo R, Luque E, Gascón F, Feijóo M, Cruz AH, Sánchez-López F, Túnez I Eur J Pharmacol. 2014 Feb 25; 730C:26-30. PMID: 24582759. Abstract
CSF levels of YKL-40 are increased in MS and replaces with immunosuppressive treatment. Malmeström C, Axelsson M, Lycke J, Zetterberg H, Blennow K, Olsson B J Neuroimmunol. 2014 Feb 13. PMID: 24582001. Abstract
Benefit of additional screening for progressive multifocal leukoencephalopathy in patients with multiple sclerosis taking natalizumab: a decision analysis. Landy DC, Hecht EM Clin Neuropharmacol. 2014 Mar-Apr; 37(2):45-51. PMID: 24614671. Abstract
Natalizumab to fingolimod washout in patients at risk of PML: When good intentions yield bad outcomes. Giovannoni G, Naismith RT Neurology. 2014 Mar 7. PMID: 24610331. Abstract
Fingolimod after natalizumab and the risk of short-term relapse. Jokubaitis VG, Li V, Kalincik T, Izquierdo G, Hodgkinson S, Alroughani R, Lechner-Scott J, Lugaresi A, Duquette P, Girard M, et al. Neurology. 2014 Mar 7. PMID: 24610329. Abstract
Melanoma complicating treatment with natalizumab for multiple sclerosis. Mullen JT, Vartanian TK, Atkins MB N Engl J Med. 2008 Feb 7; 358(6):647-8. PMID: 18256405. Abstract
JC Virus in CD34+ and CD19+ Cells in Patients With Multiple Sclerosis Treated With Natalizumab. Frohman EM, Monaco M C, Remington G, Ryschkewitsch C, Jensen PN, Johnson K, Perkins M, Liebner J, Greenberg B, Monson N, et al. JAMA Neurol. 2014 Mar 24. PMID: 24664166. Abstract
New Clues to Link Between MS Drug Tysabri and Rare Brain Disease Goodman B, WebMD, 25 Mar 2014 Accessed on 1 Apr 2014 from http://www.webmd.com/multiple-sclerosis/news/20140325/new-clues-to-link-between-ms-drug-tysabri-and-rare-brain-disease.
Editors' Pick MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study. Fox RJ, Cree BAC, De Sèze J, Gold R, Hartung H-P, Jeffery D, Kappos L, Kaufman M, Montalbán X, Weinstock-Guttman B, et al. Neurology. 2014 Apr 9. Epub 2014 Mar 28. PMID: 24682966. Abstract
The TRUST (EvaluaTion of Bladder Function in Relapsing-Remitting MUltiple Sclerosis Patients Treated with Natalizumab) Observational Study. Khatri BO, Foley JF, Fink J, Kramer JF, Cha C, You X, Warth JD, Foulds P Int J MS Care. 2014 Spring; 16(1):40-7. PMID: 24688353. Abstract
JC virus Reactivation During Prolonged Natalizumab Monotherapy for Multiple Sclerosis. Chalkias S, Dang X, Bord E, Stein MC, Kinkel PR, Sloane JA, Donnelly M, Ionete C, Houtchens MK, Buckle GJ, et al. Ann Neurol. 2014 Mar 31. PMID: 24687904. Abstract
Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial. Romme Christensen J, Ratzer R, Börnsen L, Lyksborg M, Garde E, Dyrby TB, Siebner HR, Sorensen PS, Sellebjerg F Neurology. 2014 Mar 28. PMID: 24682973. Abstract
Cryptococcal meningitis in a multiple sclerosis patient taking natalizumab. Valenzuela R M, Pula JH, Garwacki D, Cotter J, Kattah JC J Neurol Sci. 2014 Mar 11. PMID: 24680560. Abstract
Clinical and paraclinical findings in natalizumab-associated infratentorial progressive multifocal leukoencephalopathy patients. Hoepner R, Ahlbrecht J, Faissner S, Schneider R, Dahlhaus S, Adams O, Raab P, Lukas C, Chan A, Stangel M, et al. J Neurol Neurosurg Psychiatry. 2014 Apr 3. PMID: 24700881. Abstract
What to expect after natalizumab cessation in a real-life setting. Salhofer-Polanyi S, Baumgartner A, Kraus J, Maida E, Schmied M, Leutmezer F Acta Neurol Scand. 2014 Apr 10. PMID: 24720783. Abstract
Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes. Vidal-Jordana A, Sastre-Garriga J, Pérez-Miralles F, Tur C, Tintoré M, Horga A, Auger C, Río J, Nos C, Edo MC, et al. Mult Scler. 2013 Aug; 19(9):1175-81. Epub 2013 Jan 14. PMID: 23319072. Abstract
Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients. Sorensen P S, Koch-Henriksen N, Petersen T, Ravnborg M, Oturai A, Sellebjerg F J Neurol. 2014 Apr 12. Epub 2014 Apr 12. PMID: 24728334. Abstract
Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis. Kaufman M, Pardo G, Rossman H, Sweetser MT, Forrestal F, Duda P J Neurol Sci. 2014 Mar 26. PMID: 24731783. Abstract
Analysis of CD4+CD8+ double positive T cells in blood, cerebrospinal fluid and multiple sclerosis lesions. Waschbisch A, Sammet L, Schröder S, Lee D-H, Barrantes-Freer A, Stadelmann C, Linker RA Clin Exp Immunol. 2014 Apr 14. PMID: 24730443. Abstract
Editors' Pick Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis. Bergvall N, Lahoz R, Reynolds T, Korn JR Curr Med Res Opin. 2014 May 2. PMID: 24754349. Abstract
Sustained disability improvement is associated with T1 lesion volume shrinkage in natalizumab-treated patients with multiple sclerosis. Prosperini L, De Angelis F, De Angelis R, Fanelli F, Pozzilli C J Neurol Neurosurg Psychiatry. 2014 Apr 30. PMID: 24790213. Abstract
New TYSABRI® analysis at AAN annual meeting shows improved walking speed in significant number of MS patients Biogen Idec, 1 May 2014 Accessed on 15 May 2014 from https://www.biogenidec.com/press_release_details.aspx?ID=14712&Action=1&NewsId=2322&M=NewsV2&PID=61997.
Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence? Cutter GR, Stüve O Mult Scler. 2014 May 8. PMID: 24812045. Abstract
Natalizumab Use During the Third Trimester of Pregnancy. Haghikia A, Langer-Gould A, Rellensmann G, Schneider H, Tenenbaum T, Elias-Hamp B, Menck S, Zimmermann J, Herbstritt S, Marziniak M, et al. JAMA Neurol. 2014 May 12. PMID: 24821217. Abstract
B1 cells are unaffected by immune modulatory treatment in remitting-relapsing multiple sclerosis patients. Rovituso D, Heller S, Schroeter M, Kleinschnitz C, Kuerten S J Neuroimmunol. 2014 Apr 24. PMID: 24814390. Abstract
An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy. Carruthers RL, Rotstein DL, Healy BC, Chitnis T, Weiner HL, Buckle GJ Mult Scler. 2014 May 22. PMID: 24852928. Abstract
Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod. Hoepner R, Havla J, Eienbröker C, Tackenberg B, Hellwig K, Meinl I, Hohlfeld R, Gold R, Kümpfel T, Kleiter I Mult Scler. 2014 May 19. PMID: 24842961. Abstract
Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients. Muñoz-Culla M, Irizar H, Castillo-Triviño T, Sáenz-Cuesta M, Sepúlveda L, Lopetegi I, de Munain LA, Olascoaga J, Baranzini SE, Otaegui D Mult Scler. 2014 May 22. PMID: 24852919. Abstract
Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis. Gueguen A, Roux P, Deschamps R, Moulignier A, Bensa C, Savatovsky J, Heran F, Gout O J Neurol Neurosurg Psychiatry. 2014 May 29. PMID: 24876183. Abstract
Age-dependent effects on the treatment response of natalizumab in MS patients. Matell H, Lycke J, Svenningsson A, Holmén C, Khademi M, Hillert J, Olsson T, Piehl F Mult Scler. 2014 May 27. PMID: 24866201. Abstract
Neuromyelitis optica presenting with relapses under treatment with natalizumab: a case report. Lee D-H, Laemmer AB, Waschbisch A, Struffert T, Maihöfner C, Schwab S, Linker R A J Med Case Rep. 2014; 8(1):155. Epub 2014 May 19. PMID: 24886528. Abstract
Unraveling Natalizumab Effects on Deregulated miR-17 Expression in CD4(+) T Cells of Patients with Relapsing-Remitting Multiple Sclerosis. Meira M, Sievers C, Hoffmann F, Rasenack M, Kuhle J, Derfuss T, Kappos L, Lindberg RLP J Immunol Res. 2014; 2014:897249. Epub 2014 May 12. PMID: 24901013. Abstract
Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study. O'Connor P, Goodman A, Kappos L, Lublin F, Polman C, Rudick RA, Hauswirth K, Cristiano LM, Forrestal F, Duda P Neurology. 2014 Jun 4. PMID: 24898925. Abstract
Natalizumab (BG00002) Re-Initiation of Dosing. (STRATA) ClinicalTrials.gov, 4 Apr 2014 Accessed on 12 Jun 2014 from http://www.clinicaltrials.gov/ct2/show/NCT00297232.
Early Treatment with Anti-VLA-4 mAb Can Prevent the Infiltration and/or Development of Pathogenic CD11b+CD4+ T Cells in the CNS during Progressive EAE. Mindur JE, Ito N, Dhib-Jalbut S, Ito K PLoS One. 2014; 9(6):e99068. Epub 2014 Jun 04. PMID: 24896098. Abstract
Drug-induced thrombocytopenia secondary to natalizumab treatment. Cachia D, Izzy S, Berriosmorales I, Ionete C BMJ Case Rep. 2014; 2014. PMID: 24879724. Abstract
Natalizumab Continued Past 24 Months Safely in MS Keller DM, Medscape, 12 Jun 2014 Accessed on 19 Jun 2014 from http://www.medscape.com/viewarticle/826643?src=rss#1.
Safety and efficacy of natalizumab in Belgian multiple sclerosis patients: subgroup analysis of the natalizumab observational program. van Pesch V, Bartholomé E, Bissay V, Bouquiaux O, Bureau M, Caekebeke J, Debruyne J, Declercq I, Decoo D, Denayer P, et al. Acta Neurol Belg. 2014 Jun 11. Epub 2014 Jun 11. PMID: 24915752. Abstract
Effects of natalizumab on oligoclonal bands in the cerebrospinal fluid of multiple sclerosis patients: A longitudinal study. Mancuso R, Franciotta D, Rovaris M, Caputo D, Sala A, Hernis A, Agostini S, Calvo M, Clerici M Mult Scler. 2014 Jun 16. PMID: 24948690. Abstract
Severe anemia in a patient with multiple sclerosis treated with natalizumab. Simone A M, Ferraro D, Vitetta F, Marasca R, Bonacorsi G, Pinelli G, Federzoni L, Nichelli P F, Sola P Neurology. 2014 Jun 18. PMID: 24944259. Abstract
Editors' Pick Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab: Evidence From an Italian Spontaneous, Prospective, and Observational Study (the TY-STOP Study). Clerico M, Schiavetti I, De Mercanti SF, Piazza F, Gned D, Brescia Morra V, Lanzillo R, Ghezzi A, Bianchi A, Salemi G, et al. JAMA Neurol. 2014 Jun 30. Epub 1969 Dec 31. PMID: 24977406. Abstract
The use of cytokine signature patterns: separating drug naïve, interferon and natalizumab-treated multiple sclerosis patients. O'Connell KE, Mok T, Sweeney B, Ryan AM, Dev KK Autoimmunity. 2014 Jun 30:1-7. PMID: 24974887. Abstract
[Pharmacoeconomic analysis of the efficacy of natalizumab in relapsing-remitting multiple sclerosis]. Zh Nevrol Psikhiatr Im S S Korsakova. 2014; 114(5):65-9. PMID: 24988963. Abstract
Natalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy. Totaro R, Lugaresi A, Bellantonio P, Danni M, Costantino G, Gasperini C, Florio C, Pucci E, Maddestra M, Spitaleri D, et al. Int J Immunopathol Pharmacol. 2014 Jul-Sep; 27(2):147-54. PMID: 25004826. Abstract
No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: a comparative analysis of different approaches during the first year of natalizumab discontinuation. Capobianco M, di Sapio A, Malentacchi M, Malucchi S, Matta M, Sperli F, Bertolotto A Eur J Neurol. 2014 Jul 3. PMID: 24995482. Abstract
Cervical dysplasia associated with the use of natalizumab. Rolfes L, Lokhorst B, Samijn J, van Puijenbroek E Neth J Med. 2013 Nov; 71(9):494-5. PMID: 24218428. Abstract
Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis. Bergvall N, Petrilla AA, Karkare SU, Lahoz R, Agashivala N, Pradhan A, Capkun G, Makin C, Balderston McGuiness C, Korn JR J Med Econ. 2014 Jul 23:1-12. PMID: 25019581. Abstract
Multiple sclerosis symptom recrudescence at the end of the natalizumab dosing cycle. Ratchford JN, Brock-Simmons R, Augsburger A, Steele SU, Mohn K, Rhone M, Bo J, Costello K Int J MS Care. 2014 Summer; 16(2):92-8. PMID: 25061433. Abstract
Treatment satisfaction in multiple sclerosis. Glanz BI, Musallam A, Rintell DJ, Chitnis T, Weiner HL, Healy BC Int J MS Care. 2014 Summer; 16(2):68-75. PMID: 25061430. Abstract
JC virus urinary excretion and seroprevalence in natalizumab-treated multiple sclerosis patients. Delbue S, Elia F, Carloni C, Pecchenini V, Franciotta D, Gastaldi M, Colombo E, Signorini L, Carluccio S, Bellizzi A, et al. J Neurovirol. 2014 Jul 23. Epub 2014 Jul 23. PMID: 25052191. Abstract
JCV GCN in a natalizumab-treated MS patient is associated with mutations of the VP1 capsid gene. Agnihotri SP, Dang X, Carter JL, Fife TD, Bord E, Batson S, Koralnik IJ Neurology. 2014 Jul 18. PMID: 25037207. Abstract
Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy. Vennegoor A, Rispens T, Van Oosten B, Wattjes MP, Wondergem M, Teunissen CE, Van der Kleij D, Uitdehaag BMJ, Polman CH, Killestein J Mult Scler. 2014 Jul 30. PMID: 25078275. Abstract
Effect of natalizumab treatment on circulating plasmacytoid dendritic cells: a cross-sectional observational study in patients with multiple sclerosis. Kivisäkk P, Francois K, Mbianda J, Gandhi R, Weiner HL, Khoury SJ PLoS One. 2014; 9(7):e103716. Epub 2014 Jul 30. PMID: 25075741. Abstract
Anti-Human Herpesvirus 6A/B IgG Correlates with Relapses and Progression in Multiple Sclerosis. Ortega-Madueño I, Garcia-Montojo M, Dominguez-Mozo M I, Garcia-Martinez A, Arias-Leal A M, Casanova I, Arroyo R, Alvarez-Lafuente R PLoS One. 2014; 9(8):e104836. Epub 2014 Aug 11. PMID: 25110949. Abstract
VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells. Schneider-Hohendorf T, Rossaint J, Mohan H, Böning D, Breuer J, Kuhlmann T, Gross CC, Flanagan K, Sorokin L, Vestweber D, et al. J Exp Med. 2014 Aug 25; 211(9):1833-46. Epub 2014 Aug 18. PMID: 25135296. Abstract
Are natural killer cells involved in multiple sclerosis etiology? Evidences from NKp46/NCR1 receptor modulation in an observational study. Galuppo M, Giacoppo S, Sessa E, Bramanti P, Mazzon E J Neurol Sci. 2014 Jul 30. PMID: 25115502. Abstract
Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study. Ebrahimi N, Herbstritt S, Gold R, Amezcua L, Koren G, Hellwig K Mult Scler. 2014 Aug 26. PMID: 25159275. Abstract
Massive exacerbation of multiple sclerosis after withdrawal and early restart of treatment with natalizumab. Beume L-A, Dersch R, Fuhrer H, Stich O, Rauer S, Niesen WD J Clin Neurosci. 2014 Aug 20. PMID: 25150761. Abstract
The Clinical Meaning of Walking Speed as Measured by the Timed 25-Foot Walk in Patients With Multiple Sclerosis. Cohen JA, Krishnan AV, Goodman AD, Potts J, Wang P, Havrdova E, Polman C, Rudick RA JAMA Neurol. 2014 Sep 1. PMID: 25178496. Abstract
MRI pattern in asymptomatic natalizumab-associated PML. Wattjes MP, Vennegoor A, Steenwijk MD, de Vos M, Killestein J, van Oosten BW, Mostert J, Siepman DA, Moll W, van Golde AEL, et al. J Neurol Neurosurg Psychiatry. 2014 Sep 9. PMID: 25205744. Abstract
Multiple sclerosis treatment with natalizumab: analysis of a hospital-based cohort. Carvalho A T, Abreu P, Sá M J Acta Med Port. 2014 Jul-Aug; 27(4):437-43. Epub 2014 Aug 29. PMID: 25203951. Abstract
Are Natalizumab and Fingolimod Analogous Second-Line Options for the Treatment of Relapsing-Remitting Multiple Sclerosis? A Clinical Practice Observational Study. Gajofatto A, Bianchi M R, Deotto L, Benedetti M D Eur Neurol. 2014 Sep 6; 72(3-4):173-180. Epub 2014 Sep 06. PMID: 25226868. Abstract
Recurrence of disease activity after repeated Natalizumab withdrawals. Ferrè L, Moiola L, Sangalli F, Radaelli M, Barcella V, Comi G, Martinelli V Neurol Sci. 2014 Sep 24. Epub 2014 Sep 24. PMID: 25249399. Abstract
Anti-JCV antibody levels in serum or plasma further define risk of natalizumab-associated PML. Plavina T, Subramanyam M, Bloomgren G, Richman S, Pace A, Lee S, Schlain B, Campagnolo D, Belachew S, Ticho B Ann Neurol. 2014 Oct 1. PMID: 25273271. Abstract
Natalizumab for the prevention of post-partum relapses in women with multiple sclerosis. Vukusic S, Durand-Dubief F, Benoit A, Marignier R, Frangoulis B, Confavreux C Mult Scler. 2014 Oct 10. PMID: 25305253. Abstract
JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level. Lanzillo R, Liuzzi R, Vallefuoco L, Moccia M, Amato L, Vacca G, Vacchiano V, Portella G, Brescia Morra V Ther Clin Risk Manag. 2014; 10:807-14. Epub 2014 Oct 09. PMID: 25328396. Abstract
Accumulation and therapeutic modulation of 6-sulfo LacNAc(+) dendritic cells in multiple sclerosis. Thomas K, Dietze K, Wehner R, Metz I, Tumani H, Schultheiß T, Günther C, Schäkel K, Reichmann H, Brück W, et al. Neurol Neuroimmunol Neuroinflamm. 2014 Oct; 1(3):e33. Epub 2014 Sep 18. PMID: 25340085. Abstract
Extended interval dosing of natalizumab: a two-center, 7-year experience. Bomprezzi R, Pawate S Ther Adv Neurol Disord. 2014 Sep; 7(5):227-31. PMID: 25342976. Abstract
The efficacy and safety of natalizumab for the treatment of multiple sclerosis in Portugal: a retrospective study. Sousa L, de Sa J, Sa MJ, Cerqueira JJ, Martins-Silva A, En Nombre Del Portugal Experience With Natalizumab Study Group Snapshot E N D P E W N S Rev Neurol. 2014 Nov 1; 59(9):399-406. PMID: 25342053. Abstract
Risk for nevus transformation and melanoma proliferation and invasion during natalizumab treatment: four years of dermoscopic follow-up with immunohistological studies and proliferation and invasion assays. Pharaon M, Tichet M, Lebrun-Frénay C, Tartare-Deckert S, Passeron T JAMA Dermatol. 2014 Aug; 150(8):901-3. PMID: 24919481. Abstract
Vision in a Phase 3 Trial of Natalizumab for Multiple Sclerosis: Relation to Disability and Quality of Life. Chahin S, Balcer LJ, Miller DM, Zhang A, Galetta SL J Neuroophthalmol. 2014 Nov 3. PMID: 25370598. Abstract
Immune reconstitution inflammatory syndrome mimicking progressive multifocal leucoencephalopathy in a multiple sclerosis patient treated with natalizumab: a case report and review of the literature. Evangelopoulos M-E, Koutoulidis V, Kilidireas K, Evangelopoulos D-S, Nakas G, Andreadou E, Moulopoulos L-A J Clin Med Res. 2015 Jan; 7(1):65-8. Epub 2014 Oct 16. PMID: 25368707. Abstract
Disease modifying drugs modulate endogenous secretory receptor for advanced glycation end-products, a new biomarker of clinical relapse in multiple sclerosis. Sternberg Z, Sternberg D, Drake A, Chichelli T, Yu J, Hojnacki D J Neuroimmunol. 2014 Sep 15; 274(1-2):197-201. Epub 2014 Jul 15. PMID: 25064498. Abstract
Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF. Warnke C, Stettner M, Lehmensiek V, Dehmel T, Mausberg AK, von Geldern G, Gold R, Kümpfel T, Hohlfeld R, Mäurer M, et al. Mult Scler. 2014 Nov 12. PMID: 25392339. Abstract
Brain atrophy in natalizumab-treated patients: A 3-year follow-up. Sastre-Garriga J, Tur C, Pareto D, Vidal-Jordana A, Auger C, Río J, Huerga E, Tintoré M, Rovira A, Montalban X Mult Scler. 2014 Nov 12. PMID: 25392330. Abstract
Significant clinical worsening after natalizumab withdrawal: Predictive factors. Vidal-Jordana A, Tintoré M, Tur C, Pérez-Miralles F, Auger C, Río J, Nos C, Arrambide G, Comabella M, Galán I, et al. Mult Scler. 2014 Nov 12. PMID: 25392320. Abstract
Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden. O'Day K, Meyer K, Stafkey-Mailey D, Watson C J Med Econ. 2014 Nov 25:1-22. PMID: 25422991. Abstract
Outcome and survival of asymptomatic PML in natalizumab-treated MS patients. Dong-Si T, Richman S, Wattjes MP, Wenten M, Gheuens S, Philip J, Datta S, McIninch J, Bozic C, Bloomgren G, et al. Ann Clin Transl Neurol. 2014 Oct; 1(10):755-64. Epub 2014 Oct 09. PMID: 25493267. Abstract
Natalizumab improves ambulation in relapsing-remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM. Voloshyna N, Havrdová E, Hutchinson M, Nehrych T, You X, Belachew S, Hotermans C, Paes D Eur J Neurol. 2014 Dec 15. PMID: 25511792. Abstract
PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation. Killestein J, Vennegoor A, van Golde AEL, Bourez RLJH, Wijlens MLB, Wattjes MP Case Rep Neurol Med. 2014; 2014:307872. Epub 2014 Nov 23. PMID: 25506447. Abstract
Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab. Kitley J, Evangelou N, Küker W, Jacob A, Leite IM, Palace J J Neurol Sci. 2014 Feb 4. PMID: 24576801. Abstract
Natalizumab-related anaphylactoid reactions in MS patients are associated with HLA class II alleles. de la Hera B, Urcelay E, Brassat D, Chan A, Vidal-Jordana A, Salmen A, Villar L M, Alvarez-Cermeño J C, Izquierdo G, Fernández O, et al. Neurol Neuroimmunol Neuroinflamm. 2014 Dec; 1(4):e47. Epub 2014 Dec 11. PMID: 25520955. Abstract
Switch to natalizumab vs fingolimod in active relapsing-remitting multiple sclerosis. Kalincik T, Horakova D, Spelman T, Jokubaitis V, Trojano M, Lugaresi A, Izquierdo G, Rozsa C, Grammond P, Alroughani R, et al. Ann Neurol. 2014 Dec 27. PMID: 25546031. Abstract
Transfer of Natalizumab into Breast Milk in a Mother with Multiple Sclerosis. Baker TE, Cooper SD, Kessler L, Hale TW J Hum Lact. 2015 Jan 13. PMID: 25586712. Abstract
lipid-specific IgM bands in csf associated with a reduced risk of developing pml during treatment with natalizumab. Villar LM, Costa-Frossard L, Masterman T, Fernandez O, Montalban X, Casanova B, Izquierdo G, Coret F, Tumani H, Saiz A, et al. Ann Neurol. 2015 Jan 7. PMID: 25581547. Abstract
High interindividual variability in the CD4/CD8 T cell ratio and natalizumab concentration levels in the cerebrospinal fluid of patients with multiple sclerosis. Harrer A, Pilz G, Wipfler P, Oppermann K, Sellner J, Hitzl W, Haschke-Becher E, Afazel S, Rispens T, van der Kleij D, et al. Clin Exp Immunol. 2015 Jan 20. PMID: 25603898. Abstract
Natalizumab discontinuation and disease restart in pregnancy: a case series. De Giglio L, Gasperini C, Tortorella C, Trojano M, Pozzilli C Acta Neurol Scand. 2015 Jan 18. PMID: 25598313. Abstract
Natalizumab restores aberrant miRNA expression profile in multiple sclerosis and reveals a critical role for miR-20b. Ingwersen J, Menge T, Wingerath B, Kaya D, Graf J, Prozorovski T, Keller A, Backes C, Beier M, Scheffler M, et al. Ann Clin Transl Neurol. 2015 Jan; 2(1):43-55. Epub 2014 Dec 05. PMID: 25642434. Abstract
Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy. Vennegoor A, van Rossum JA, Polman CH, Wattjes MP, Killestein J Mult Scler. 2015 Feb 6. PMID: 25662344. Abstract
Cyclical suicidal ideation following natalizumab infusion for multiple sclerosis. Nagesh O, Bastiampillai T, Fisher L, Mohan T Aust N Z J Psychiatry. 2015 Feb 16. PMID: 25688123. Abstract
Severe anemia in a patient with multiple sclerosis treated with natalizumab. Seibert JB, Alvarez E Neurology. 2015 Feb 24; 84(8):861. PMID: 25713115. Abstract
Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads. Prosperini L, Annovazzi P, Capobianco M, Capra R, Buttari F, Gasperini C, Galgani S, Solaro C, Centonze D, Bertolotto A, et al. Mult Scler. 2015 Feb 19. PMID: 25698174. Abstract
Increased relapse activity for multiple sclerosis natalizumab users who become nonpersistent: a retrospective study. McQueen BR, Livingston T, Vollmer T, Corboy J, Buckley B, Allen R R, Nair K, Campbell JD J Manag Care Spec Pharm. 2015 Mar; 21(3):210-8. PMID: 25726030. Abstract
Improvement in Fatigue during Natalizumab Treatment is Linked to Improvement in Depression and Day-Time Sleepiness. Penner I-K, Sivertsdotter E C, Celius EG, Fuchs S, Schreiber K, Berkö S, Svenningsson A, TYNERGY trial investigators Front Neurol. 2015; 6:18. Epub 2015 Feb 23. PMID: 25755648. Abstract
Enhanced Axonal Metabolism during Early Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis. Wiebenga OT, Klauser AM, Schoonheim MM, Nagtegaal GJA, Steenwijk MD, van Rossum J, Polman CH, Barkhof F, Pouwels PJW, Geurts JJG AJNR Am J Neuroradiol. 2015 Mar 5. PMID: 25742985. Abstract
Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy. Dong-Si T, Gheuens S, Gangadharan A, Wenten M, Philip J, McIninch J, Datta S, Richert N, Bozic C, Bloomgren G, et al. J Neurovirol. 2015 Mar 14. Epub 2015 Mar 14. PMID: 25771865. Abstract
Hematopoietic mobilization: Potential biomarker of response to natalizumab in multiple sclerosis. Mattoscio M, Nicholas R, Sormani MP, Malik O, Lee JS, Waldman AD, Dazzi F, Muraro PA Neurology. 2015 Mar 11. PMID: 25762712. Abstract
Effectiveness of Natalizumab in Patients with Highly Active Relapsing Remitting Multiple Sclerosis. Cobo-Calvo Á, Bau L, Matas E, Romero-Pinel L, Mañé Martínez AM, Majós C, Martínez Yélamos S Eur Neurol. 2015 Mar 13; 73(3-4):220-229. Epub 2015 Mar 13. PMID: 25792347. Abstract
Serological evidence of increased susceptibility to varicella-zoster virus reactivation or reinfection in natalizumab-treated patients with multiple sclerosis. Kohlmann R, Salmen A, Chan A, Knabbe C, Diekmann J, Brockmeyer N, Skaletz-Rorowski A, Michalik C, Gold R, Überla K Mult Scler. 2015 Mar 31. PMID: 25828755. Abstract
Soluble VCAM-1 impairs human brain endothelial barrier integrity via integrin α-4-transduced outside-in signalling. Haarmann A, Nowak E, Deiß A, van der Pol S, Monoranu C-M, Kooij G, Müller N, van der Valk P, Stoll G, de Vries HE, et al. Acta Neuropathol. 2015 Mar 27. Epub 2015 Mar 27. PMID: 25814153. Abstract
Natalizumab in spinal multiple sclerosis in a daily clinical setting. Zecca C, Heldner MR, Kamm CP, Riccitelli GC, Disanto G, Caporro M, Cianfoni A, Pravatà E, Gobbi C Expert Opin Biol Ther. 2015 May; 15(5):633-40. Epub 2015 Apr 03. PMID: 25840751. Abstract
Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients. Sangalli F, Moiola L, Ferrè L, Radaelli M, Barcella V, Rodegher M, Colombo B, Martinelli Boneschi F, Martinelli V, Comi G Mult Scler Relat Disord. 2014 Jul; 3(4):520-6. Epub 2014 Apr 13. PMID: 25877065. Abstract
Extending Treatment Up To Eight Weeks With Infusion Medication Shown Safe and Effective in Patients with Multiple Sclerosis NYU Langone Medical Center, 22 Apr 2015 Accessed on 28 Apr 2015 from http://nyulangone.org/press-releases/extending-treatment-up-to-eight-weeks-with-infusion-medication-shown-safe-and-effective-in-patients-with-multiple-sclerosis.
Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis. Frisell T, Forsberg L, Nordin N, Kiesel C, Alfredsson L, Askling J, Hillert J, Olsson T, Piehl F Mult Scler. 2015 Apr 28. PMID: 25921036. Abstract
Comparative efficacy of switching to natalizumab in active multiple sclerosis. Spelman T, Kalincik T, Zhang A, Pellegrini F, Wiendl H, Kappos L, Tsvetkova L, Belachew S, Hyde R, Verheul F, et al. Ann Clin Transl Neurol. 2015 Apr; 2(4):373-87. Epub 2015 Feb 27. PMID: 25909083. Abstract
ACUTE RETINAL NECROSIS AND IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN A NATALIZUMAB-TREATED PATIENT WITH MULTIPLE SCLEROSIS. Saraiva VS Retin Cases Brief Rep. 2015 Apr 29. PMID: 25933353. Abstract
Tysabri Review Launched in Europe Medscape, 8 May 2015 Accessed on 12 May 2015 from http://www.medscape.com/viewarticle/844431.
Biogen Idec Becomes Biogen Biogen, 23 Mar 2015 Accessed on 7 Apr 2015 from http://biogen.newshq.businesswire.com/press-release/corporate/biogen-idec-becomes-biogen.
CD4 cell response to interval therapy with natalizumab. Berkovich R, Togasaki DM, Cen SY, Steinman L Ann Clin Transl Neurol. 2015 May; 2(5):570-4. Epub 2015 Mar 06. PMID: 26000328. Abstract
Editors' Pick Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS. Kappos L, Radue E-W, Comi G, Montalban X, Butzkueven H, Wiendl H, Giovannoni G, Hartung H-P, Derfuss T, Naegelin Y, et al. Neurology. 2015 May 29. Epub 1969 Dec 31. PMID: 26024899. Abstract
Impact of natalizumab treatment on fatigue, mood, and aspects of cognition in relapsing-remitting multiple sclerosis. Kunkel A, Fischer M, Faiss J, Dähne D, Köhler W, Faiss JH Front Neurol. 2015; 6:97. Epub 2015 May 11. PMID: 26029156. Abstract
Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS). (REFINE) ClinicalTrials.gov, 2 Apr 2015 Accessed on 23 Jun 2015 from https://www.clinicaltrials.gov/ct2/show/NCT01405820.
Natalizumab SC Similar to IV Every 4 Weeks for MS Medscape, 22 Jun 2015 Accessed on 23 Jun 2015 from http://www.medscape.com/viewarticle/846795.
Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment. Castellazzi M, Delbue S, Elia F, Gastaldi M, Franciotta D, Rizzo R, Bellini T, Bergamaschi R, Granieri E, Fainardi E Dis Markers. 2015; 2015:901312. Epub 2015 May 26. PMID: 26101453. Abstract
Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor). Klotz L, Grützke B, Eveslage M, Deppe M, Gross CC, Kirstein L, Posevitz-Fejfar A, Schneider-Hohendorf T, Schwab N, Meuth SG, et al. BMC Neurol. 2015; 15:96. Epub 2015 Jun 23. PMID: 26099927. Abstract
Surgical management of malignant cerebral edema secondary to immune reconstitution inflammatory syndrome from natalizumab-associated progressive multifocal encephalopathy. Tan LA, Lopes DK J Clin Neurosci. 2015 Jun 24. PMID: 26115897. Abstract
Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients. Johnson BH, Bonafede MM, Watson C CNS Drugs. 2015 Jun 26. PMID: 26113055. Abstract
Balò's concentric sclerosis: still to be considered as a variant of multiple sclerosis? Pietroboni AM, Arighi A, De Riz MA, Ghezzi L, Calvi A, Avignone S, Scola E, Galimberti D, Triulzi F, Scarpini E Neurol Sci. 2015 Jun 25. Epub 2015 Jun 25. PMID: 26109007. Abstract
Natalizumab Significantly Improves Cognitive Impairment over Three Years in MS: Pattern of Disability Progression and Preliminary MRI Findings. Mattioli F, Stampatori C, Bellomi F, Scarpazza C, Capra R PLoS One. 2015; 10(7):e0131803. Epub 2015 Jul 06. PMID: 26148120. Abstract
Hematologic modifications in natalizumab-treated multiple sclerosis patients: An 18-month longitudinal study. Bridel C, Beauverd Y, Samii K, Lalive PH Neurol Neuroimmunol Neuroinflamm. 2015 Aug; 2(4):e123. Epub 2015 Jun 18. PMID: 26140281. Abstract
Non-Hodgkin Lymphoma of the Stomach in a Patient Treated with Natalizumab. Law JY, Kim DW, Sturgis A, Naina HV Clin Med Insights Oncol. 2015; 9:61-3. Epub 2015 Jul 01. PMID: 26157340. Abstract
Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients. Basnyat P, Hagman S, Kolasa M, Koivisto K, Verkkoniemi-Ahola A, Airas L, Elovaara I Mult Scler Relat Disord. 2015 Jul; 4(4):334-8. PMID: 26195052. Abstract
Natalizumab modulates the humoral response against HERV-Wenv73-88 in a follow-up study of Multiple Sclerosis patients. Arru G, Caggiu E, Leoni S, Mameli G, Pugliatti M, Sechi G P, Sechi LA J Neurol Sci. 2015 Jul 8. PMID: 26190523. Abstract
Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells. Spadaro M, Caldano M, Marnetto F, Lugaresi A, Bertolotto A J Neuroinflammation. 2015; 12:146. Epub 2015 Aug 12. PMID: 26259673. Abstract
Natalizumab treatment in multiple sclerosis: the experience from two Brazilian MS centers. de Oliveira E M L, Simm R F, Dasic G, de Morais M M, Perreira S L D A, Callegaro D Arq Neuropsiquiatr. 2015 Sep; 73(9):736-40. PMID: 26352489. Abstract
Anti-JC virus seroprevalence in a Finnish MS cohort. Kolasa M, Hagman S, Verkkoniemi-Ahola A, Airas L, Koivisto K, Elovaara I Acta Neurol Scand. 2015 Sep 8. PMID: 26347001. Abstract
Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis. Novakova L, Axelsson M, Malmeström C, Zetterberg H, Björkhem I, Karrenbauer V D, Lycke J J Neurol Sci. 2015 Aug 29. PMID: 26342940. Abstract
MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS. Wattjes MP, Wijburg MT, Vennegoor A, Witte BI, de Vos M, Richert ND, Uitdehaag B M, Barkhof F, Killestein J, Dutch-Belgian Natalizumab-associated PML study group J Neurol Neurosurg Psychiatry. 2015 Sep 14. PMID: 26369555. Abstract
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Tramacere I, Giovane C D, Salanti G, D'Amico R, Filippini G Cochrane Database Syst Rev. 2015 Sep 18; 9:CD011381. PMID: 26384035. Abstract
Editors' Pick Natalizumab in the pediatric MS population: results of the Italian registry. Ghezzi A, Moiola L, Pozzilli C, Brescia-Morra V, Gallo P, Grimaldi L M E, Filippi M, G G C, MS Study Group-Italian Society of Neurology BMC Neurol. 2015; 15(1):174. Epub 2015 Sep 25. PMID: 26407848. Abstract
Upregulation of integrin expression on monocytes in multiple sclerosis patients treated with natalizumab. Dallari S, Franciotta D, Carluccio S, Signorini L, Gastaldi M, Colombo E, Bergamaschi R, Elia F, Villani S, Ferrante P, et al. J Neuroimmunol. 2015 Oct 15; 287:76-9. Epub 2015 Aug 14. PMID: 26439965. Abstract
Asymptomatic Progressive Multifocal Leukoencephalopathy Associated with Natalizumab: Diagnostic Precision with MR Imaging. Hodel J, Outteryck O, Dubron C, Dutouquet B, Benadjaoud M A, Duhin E, Verclytte S, Zins M, Luciani A, Rahmouni A, et al. Radiology. 2015 Oct 5:150673. PMID: 26436861. Abstract
PML risk stratification using anti-JCV antibody index and L-selectin. Schwab N, Schneider-Hohendorf T, Pignolet B, Spadaro M, Görlich D, Meinl I, Windhagen S, Tackenberg B, Breuer J, Cantó E, et al. Mult Scler. 2015 Oct 2. PMID: 26432858. Abstract
New Data Show Longer Tysabri Dosing Interval in MS Is Feasible Gever J, MedPage Today, 7 Oct 2015 Accessed on 13 Oct 2015 from http://www.medpagetoday.com/clinical-context/MultipleSclerosis/53960.
Pregnancy Does Not Prove Neuroprotective for Women with MS Who Stop Taking Natalizumab Susman E, Neurology Today, 9 Oct 2015 Accessed on 13 Oct 2015 from http://journals.lww.com/neurotodayonline/blog/NeurologyTodayConferenceReportersCongressofECTRIMS/pages/post.aspx?PostID=4.
Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis. Signoriello E, Lanzillo R, Brescia Morra V, Di Iorio G, Fratta M, Carotenuto A, Lus G Mult Scler. 2015 Oct 9. PMID: 26453682. Abstract
Anti-JC virus antibody titres increase over time with natalizumab treatment. Raffel J, Gafson AR, Malik O, Nicholas R Mult Scler. 2015 Oct 8. PMID: 26449743. Abstract
Age-Dependent Seroprevalence of JCV Antibody in Children. Hennes E M, Kornek B, Huppke P, Reindl M, Rostasy K, Berger T Neuropediatrics. 2015 Oct 19. Epub 2015 Oct 19. PMID: 26479766. Abstract
Natalizumab reduces relapse clinical severity and improves relapse recovery in MS. Lublin FD, Cutter G, Giovannoni G, Pace A, Campbell NR, Belachew S Mult Scler Relat Disord. 2014 Nov; 3(6):705-11. Epub 2014 Sep 06. PMID: 25891549. Abstract
Biogen Reports Top-Line Results from Phase 3 Study Evaluating Natalizumab in Secondary Progressive MS Biogen, 21 Oct 2015 Accessed on 27 Oct 2015 from http://media.biogen.com/press-release/corporate/biogen-reports-top-line-results-phase-3-study-evaluating-natalizumab-seconda.
Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients. Domínguez-Mozo MI, García-Montojo M, Arias-Leal A, García-Martínez Á, Santiago JL, Casanova I, Galán V, Arroyo R, Fernández-Arquero M, Alvarez-Lafuente R Eur J Neurol. 2015 Oct 25. PMID: 26498276. Abstract
Progressive multifocal leukoencephalopathy associated to natalizumab extended dosing regimen. Hervás J V, Presas-Rodríguez S, Crespo-Cuevas A M, Canento T, Lozano-Sánchez M, Massuet-Vilamajó A, Ramo-Tello C Neurodegener Dis Manag. 2015 Oct 30. PMID: 26517599. Abstract
7T MRI in natalizumab-associated PML and ongoing MS disease activity: A case study. Sinnecker T, Othman J, Kühl M, Mekle R, Selbig I, Niendorf T, Kunkel A, Wienecke P, Kern P, Paul F, et al. Neurol Neuroimmunol Neuroinflamm. 2015 Dec; 2(6):e171. Epub 2015 Oct 29. PMID: 26568970. Abstract
Natalizumab-induced hepatic injury: A case report and review of literature. Antezana A, Sigal S, Herbert J, Kister I Mult Scler Relat Disord. 2015 Nov; 4(6):495-8. Epub 2015 Sep 03. PMID: 26590653. Abstract
Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS Centers. Lo Re M, Capobianco M, Ragonese P, Realmuto S, Malucchi S, Berchialla P, Salemi G, Bertolotto A Neurol Ther. 2015 Dec; 4(2):147-57. Epub 2015 Dec 08. PMID: 26647006. Abstract
Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE. Kaufman M, Cree BAC, De Sèze J, Fox RJ, Gold R, Hartung H-P, Jeffery D, Kappos L, Montalbán X, Weinstock-Guttman B, et al. J Neurol. 2015 Feb; 262(2):326-36. Epub 2014 Nov 09. PMID: 25381458. Abstract
CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients. Lieberman LA, Zeng W, Singh C, Wang W, Otipoby KL, Loh C, Plavina T, Gorelik L, Ransohoff RM, Cahir-McFarland E Neurology. 2015 Dec 30. PMID: 26718566. Abstract
Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone. Öhrfelt A, Axelsson M, Malmeström C, Novakova L, Heslegrave A, Blennow K, Lycke J, Zetterberg H Mult Scler. 2016 Jan 11. PMID: 26754805. Abstract
The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapies. McKay FC, Gatt PN, Fewings N, Parnell GP, Schibeci SD, Basuki MAI, Powell JE, Goldinger A, Fabis-Pedrini MJ, Kermode AG, et al. Clin Immunol. 2016 Jan 4; 163:96-107. PMID: 26762769. Abstract
Natalizumab treatment for multiple sclerosis inducing a toxic acute myocardial damage. Is there any relationship? Fama' F, Dattola V, Cicciu' M, Buccafusca M, Russo M, Lo Presti D, Dattilo G, Di Bella G Int J Cardiol. 2016 Mar 1; 206:127-8. Epub 2016 Jan 08. PMID: 26788687. Abstract
Effects of fumarates on circulating and CNS myeloid cells in multiple sclerosis. Michell-Robinson MA, Moore CS, Healy LM, Osso LA, Zorko N, Grouza V, Touil H, Poliquin-Lasnier L, Trudelle A-M, Giacomini PS, et al. Ann Clin Transl Neurol. 2016 Jan; 3(1):27-41. Epub 2015 Dec 02. PMID: 26783548. Abstract
Progressive outer retinal necrosis in a multiple sclerosis patient on natalizumab. Bourre B, Gueudry J, Lefaucheur R, Borden A, Maltête D, Patel SS, Van Tassel S H, Gupta MP, Orlin A, Nealon NM Neurology. 2016 Jan 19; 86(3):312-3. PMID: 26783270. Abstract
Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation. Weinstock-Guttman B, Hagemeier J, Kavak KS, Saini V, Patrick K, Ramasamy DP, Nadeem M, Carl E, Hojnacki D, Zivadinov R J Neurol Neurosurg Psychiatry. 2016 Jan 18. PMID: 26780938. Abstract
Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP). Wiendl H, Butzkueven H, Kappos L, Trojano M, Pellegrini F, Paes D, Zhang A, Belachew S, Tysabri® Observational Program(TOP) Investigators PLoS One. 2016; 11(1):e0144834. Epub 2016 Jan 15. PMID: 26771747. Abstract
Lipocalin-2 is increased in progressive multiple sclerosis and inhibits remyelination. Al Nimer F, Elliott C, Bergman J, Khademi M, Dring AM, Aeinehband S, Bergenheim T, Romme Christensen J, Sellebjerg F, Svenningsson A, et al. Neurol Neuroimmunol Neuroinflamm. 2016 Feb; 3(1):e191. Epub 2016 Jan 07. PMID: 26770997. Abstract
Concomitant granule cell neuronopathy in patients with natalizumab-associated PML. Wijburg MT, Siepman D, van Eijk JJJ, Killestein J, Wattjes MP J Neurol. 2016 Jan 25. PMID: 26810721. Abstract
A Randomized Trial Evaluating Various Administration Routes of Natalizumab in Multiple Sclerosis. Plavina T, Fox EJ, Lucas N, Muralidharan K K, Mikol D J Clin Pharmacol. 2016 Feb 2. PMID: 26835603. Abstract
Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study. Barbin L, Rousseau C, Jousset N, Casey R, Debouverie M, Vukusic S, De Sèze J, Brassat D, Wiertlewski S, Brochet B, et al. Neurology. 2016 Jan 29. PMID: 26826205. Abstract
Multiparametric flow cytometric analysis of whole blood reveals changes in minor lymphocyte subpopulations of multiple sclerosis patients. Teniente-Serra A, Grau-López L, Mansilla JM, Fernández-Sanmartín M, Ester Condins A, Ramo-Tello C, Martínez-Cáceres E Autoimmunity. 2016 Feb 1:1-10. PMID: 26829210. Abstract
Immune-Reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases. N'gbo N'gbo Ikazabo R, Mostosi C, Quivron B, Delberghe X, El Hafsi K, Lysandropoulos AP Clin Ther. 2016 Feb 4. PMID: 26856928. Abstract
Editors' Pick Reassessing the risk of natalizumab-associated PML. Berger JR, Fox RJ J Neurovirol. 2016 Feb 3. Epub 2016 Feb 03. PMID: 26843383. Abstract
New EMA Advice to Reduce PML Risk With Natalizumab (Tysabri) in MS Jeffrey S, Medscape, 12 Feb 2016 Accessed on 16 Feb 2016 from http://www.medscape.com/viewarticle/858883.
Extended interval dosing of natalizumab in multiple sclerosis. Zhovtis Ryerson L, Frohman TC, Foley J, Kister I, Weinstock-Guttman B, Tornatore C, Pandey K, Donnelly S, Pawate S, Bomprezzi R, et al. J Neurol Neurosurg Psychiatry. 2016 Feb 25. PMID: 26917698. Abstract
White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis. Wiebenga OT, Schoonheim MM, Hulst HE, Nagtegaal GJA, Strijbis EMM, Steenwijk MD, Polman CH, Pouwels PJW, Barkhof F, Geurts JJG AJNR Am J Neuroradiol. 2016 Mar 10. PMID: 26965463. Abstract
Disrupted balance of T cells under natalizumab treatment in multiple sclerosis. Kimura K, Nakamura M, Sato W, Okamoto T, Araki M, Lin Y, Murata M, Takahashi R, Yamamura T Neurol Neuroimmunol Neuroinflamm. 2016 Apr; 3(2):e210. Epub 2016 Mar 03. PMID: 27006971. Abstract
Acute Cryptococcal Immune Reconstitution Inflammatory Syndrome in a Patient on Natalizumab. Gundacker ND, Jordan SJ, Jones BA, Drwiega JC, Pappas PG Open Forum Infect Dis. 2016 Jan; 3(1):ofw038. Epub 2016 Feb 17. PMID: 27006962. Abstract
Th17 cells: A prognostic marker for MS rebound after natalizumab cessation? Haas J, Schneider K, Schwarz A, Korporal-Kuhnke M, Faller S, von Glehn F, Jarius S, Wildemann B Mult Scler. 2016 Mar 21. PMID: 27003947. Abstract
Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years. Zivadinov R, Hojnacki D, Bergsland N, Kennedy C, Hagemeier J, Melia R, Ramasamy DP, Durfee J, Carl E, Dwyer MG, et al. Eur J Neurol. 2016 Mar 21. PMID: 26998905. Abstract
High cumulative JC virus seroconversion rate during long-term use of natalizumab. Vennegoor A, van Rossum J, Leurs C, Wattjes MP, Rispens T, Murk JLAN, Uitdehaag BMJ, Killestein J Eur J Neurol. 2016 Mar 27. PMID: 27018481. Abstract
Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Alping P, Frisell T, Novakova L, Islam-Jakobsson P, Salzer J, Björck A, Axelsson M, Malmeström C, Fink K, Lycke J, et al. Ann Neurol. 2016 Mar 31. PMID: 27038238. Abstract
Dengue fever in patients with multiple sclerosis taking fingolimod or natalizumab. Fragoso Y D, da Gama P D, Gomes S, Khouri J M N, da Matta A P C, Mendes M F, Stella C R A V Mult Scler Relat Disord. 2016 Mar; 6:64-5. Epub 2016 Jan 28. PMID: 27063625. Abstract
Editors' Pick A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod. Koch-Henriksen N, Magyari M, Sellebjerg F, Sørensen P S Mult Scler. 2016 Apr 7. Epub 1969 Dec 31. PMID: 27055806. Abstract
Study Confirms Natalizumab Efficacy, Safety in Treating RRMS MPR, 17 Apr 2016 Accessed on 18 Apr 2016 from http://www.empr.com/aan-2016-multiple-sclerosis/study-confirms-natalizumab-efficacy-safety-in-treating-rrms/article/487735/.
Punctate pattern: A promising imaging marker for the diagnosis of natalizumab-associated PML. Hodel J, Darchis C, Outteryck O, Verclytte S, Deramecourt V, Lacour A, Zins M, Pruvo J-P, Vermersch P, Leclerc X Neurology. 2016 Mar 23. PMID: 27009257. Abstract
Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values. Schwab N, Schneider-Hohendorf T, Pignolet B, Breuer J, Gross CC, Göbel K, Brassat D, Wiendl H Neurol Neuroimmunol Neuroinflamm. 2016 Feb; 3(1):e195. Epub 2016 Jan 27. PMID: 26848486. Abstract